ProteinQure

ProteinQure awarded $2.5M from @GenomeCanada to advance siRNA therapeutics for glioblastoma. We also welcome Dr. Henry Friedman & Dr. Alexandra Miller to our Clinical Advisory Board. Advancing AI-designed peptides to tackle one of the toughest cancers. proteinqure.com/proteinqure-re…

We're presenting at #KSNATherapy26: Identification and Characterization of AI-Designed TFR1 Binding Peptides as Blood-Brain Shuttles for Nucleic Acid Payload Delivery. PQ404 shows binding, internalization, and transcytosis, and remains active when conjugated to siRNA. More soon!

Last month, we completed a company-wide agentic AI hackathon to create solutions to team pain points. Congrats to the people's choice winners: "Binders Keepers", a fully-functioning GPU-powered daily binder design challenge, & "Tuesday", a drug development GANTT chart assistant!

This week at the Gordon Research Conference on the Chemistry and Biology of Peptides, we shared a case study powered by our peptide drug design platform—combining cheminformatics, structure-based design, and machine learning across 6,000+ non-canonical amino acid monomers.

We were pleased to host "Western University's Women in Science" student group during their annual trip to meet Toronto teams. We were excited to share our work in drug discovery and to discuss career journeys and opportunities with this next generation of STEM professionals.

We're attending the 2026 J.P. Morgan Healthcare Conference. Connect with us directly if you're interested to discuss collaboration opportunities in peptide discovery and drug delivery, updates on our pipeline and clinical asset PQ203, or our vision and growth plans.

From CDL-Toronto’s 2017/18 Quantum cohort to leading a first-in-class clinical trial, @proteinqure has reached a defining milestone: the company’s AI-designed peptide therapy, PQ203, is now in Phase I clinical trials for advanced metastatic cancer. creativedestructionlab.com/blog/proteinqu…

There's a recent explosion of new techniques available for computational drug design, but few of them are catered towards peptide therapeutics. Today, we're presenting development and experimental validation of a peptide-specific inverse folding model at the MLSB 2025 Workshop.

We were pleased to close out the "Peptide Discovery to CMC" session at TIDES Europe 2025 with our story of PQ203 development from code to first-in-human. Innovations from early to late-stage drug development will result in live-changing treatments for patients. #TIDESEurope

This past weekend, our team "Pep(tides) in your Step" took part in the CIBC #RunForTheCure in support of the Canadian Cancer Society — because science and community move us forward together! @TorontoRun

The Boulder Peptide Symposium unites experts in the pharmaceutical development of peptide therapeutics. This week we were pleased to share the story of PQ203 from discovery to first-in-human. Peptides are rewriting what’s possible in drug discovery! @BoulderPeptide

We’re incredibly excited to share a big milestone for ProteinQure: the first patient has been dosed in our Phase I clinical trial of PQ203, a novel peptide‑drug conjugate for advanced metastatic solid tumors. Learn more: lnkd.in/dy7QZtuS

Behind every bold idea is a dedicated team. At ProteinQure, we Dare to Deliver—taking risks in translational drug discovery that push science forward, like advancing our oncology program advancing to a phase 1 clinical trial. It takes all of us to make it possible.

Today we were pleased to host ProteinQure alum @Tianyu_Lu for a "Lunch and Learn" to discuss advances in conditional protein structure generation using Protpardelle-1C (biorxiv.org/content/10.110…). Check your bias for helices at the door and imagine the binders you're missing!

Advances in peptide science are leading to a paradigm shift in drug design. This week our co-founder @jsci is sharing our strategy for structure-based drug design of a novel sortilin-targeted peptide drug conjugate at the 2025 Medicinal Chemistry Gordon Research Conference.

We shared data from our peptide discovery platform at the American Peptide Society Symposium today. Computationally designed peptide libraries offer unique advantages for targeting challenging receptors and faster hit-to-lead optimization #Peptides2025

Catch our CEO @lucasfolds on site at #BIO2025 in Boston to share progress on our lead clinical program PQ203 and to explore collaborations that accelerate peptide drug discovery through AI-driven design. Secure a BIO One-on-One slot or drop us a DM to connect!

We closed our Series A to support advancing PQ203, our first AI-designed peptide-drug conjugate into a Phase 1 #clinicaltrial in triple-negative #breastcancer, expected to begin in Q3. Read our release for more: proteinqure.com/proteinqure-ra… #AI #drugdiscovery #peptidetherapeutics

We closed our $11 M Series A. This funding drives our AI-designed peptide therapeutic into the clinic and enables us to scale our platform for precision drug delivery against tough diseases. Dare to Deliver!

From discovery to delivery, peptides face a tough path to patients. Dave Garman, VP of Translation and Development, is currently attending #TIDESUSA 2025, and sharing expertise on "Fast Tracking to First in Humans and CMC Requirements and Considerations".